CONCISE COMMUNICATIONS


DOI 10.1002/art.21501

Erratum

In the article by Kremer et al published in the August 2005 issue of Arthritis & Rheumatism (pp 2263–2271), there were several errors and omissions in the financial disclosure paragraph. It should have read as follows: “Dr. Kremer has received consulting fees (greater than $10,000) from Bristol-Myers Squibb, grant support from Amgen, Abbott, Bristol-Myers Squibb, Centocor, HGS, Roche, and Genentech, and speaking fees (less than $10,000) from all of these companies with the exception of HGS. Dr. Dougados’ center has received financial support from Bristol-Myers Squibb, Wyeth, Roche, and Abbott for conducting clinical trials. He has also participated at different advisory board meetings for all of these companies. Dr. Emery has received consulting fees (less than $10,000) from Bristol-Myers Squibb and has spoken at symposia on behalf of Bristol-Myers Squibb. He has also provided expert advice to manufacturers of other biologic agents and rheumatologic drugs, as well as lecturing on their behalf. Dr. Sibilia has received consulting fees (less than $10,000) from Bristol-Myers Squibb. Dr. Shergy is a speaker for Amgen and Centocor and is involved in clinical trials with Amgen, Centocor, Abbott, Genentech, and Lilly. Dr. Tindall is the principal investigator on studies with Genentech, Amgen, Abbott, and Bristol-Myers Squibb. Drs. Becker and Nuamah have Bristol-Myers Squibb stock options. Drs. Li and Aranda own Bristol-Myers Squibb stock. Dr. Moreland has received consulting fees (more than $10,000) from Bristol-Myers Squibb and has received honoraria from Amgen, Centocor, Genentech, Abbott, and Wyeth in the past year.”

We regret the errors.